Winton Group LTD Prometheus Biosciences, Inc. Transaction History

Winton Group LTD

  • $1.31 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$28.17 - $59.01 $205,950 - $431,422
7,311 New
7,311 $431,000

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email